Salvage brachytherapy for localized prostate cancer after radiotherapy failure

被引:190
作者
Grado, GL
Collins, JM
Kriegshauser, JS
Balch, CS
Grado, MM
Swanson, GP
Larson, TR
Wilkes, MM
Navickis, RJ
机构
[1] Mayo Clin, Dept Radiat Oncol, Scottsdale, AZ USA
[2] Mayo Clin, Dept Diagnost Radiol, Scottsdale, AZ USA
[3] Mayo Clin, Dept Urol, Scottsdale, AZ USA
[4] Scott & White Mem Hosp & Clin, Temple, TX 76508 USA
[5] Hygeria Associates, Grass Valley, CA USA
关键词
D O I
10.1016/S0090-4295(98)00492-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To evaluate the effectiveness and morbidity of salvage brachytherapy for locally recurrent or persistent prostate cancer after radiotherapy failure. Methods. In this retrospective study, 49 patients of median age 75.3 years (range 52.9 to 86.9) with biopsy-proven localized prostate cancer underwent interactive transperineal fluoroscopic-guided and biplane ultrasound-guided brachytherapy with either iodine 125 or palladium 103 after prior radiotherapy failure. Post-treatment follow-up was conducted for a median of 64.1 months (range 26.6 to 96.8) and included clinical assessment of disease status, assays of serum prostate-specific antigen (PSA) levels, and documentation of treatment-related symptoms and complications. Determination of biochemical treatment failure was based on two successive rising PSA values above the post-treatment PSA nadir value. Results. The actuarial rate of local prostate cancer control was 98% (95% confidence interval [CI] 94% to 99%). Actuarial disease-specific survival at 3 and 5 years was 89% (95% CI 73% to 96%) and 79% (95% CI 58% to 91%), respectively. At 3 and 5 years, actuarial biochemical disease-free survival was 48% (95% CI 32% to 63%) and 34% (95% CI 17% to 51%), respectively. Post-treatment PSA nadir was found to be a significant predictor of biochemical disease-free survival, Actuarial biochemical disease-free survival of patients who achieved a PSA nadir less than 0.5 ng/mL was 77% (95% CI 53% to 90%) and 56% (95% CI 25% to 78%) at 3 and 5 years, respectively. Of 49 patients, 23 (47%) achieved a post-treatment PSA nadir less than 0.5 ng/mL. The incidence of serious complications after salvage brachytherapy, such as incontinence and rectal complications, was lower than that reported after other types of salvage procedures. Conclusions. Interactive transperineal fluoroscopic-guided and biplane ultrasound-guided brachytherapy is a novel, potentially curative salvage modality for patients in whom prior radiotherapy failed. In a population of patients with poor prognosis, this modality was associated with a high rate of local prostate cancer control and a 34% actuarial rate of biochemical disease-free survival at 5 years. The incidence of major complications after salvage brachytherapy appears to be lower than that after other potentially curative salvage procedures, such as radical prostatectomy and cryoablation. Salvage brachytherapy warrants further investigation. UROLOGY 53: 2-10, 1999. (C) 1999, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:2 / 10
页数:9
相关论文
共 65 条
  • [1] SALVAGE SURGERY PLUS ANDROGEN DEPRIVATION FOR RADIORESISTANT PROSTATIC ADENOCARCINOMA
    AHLERING, TE
    LIESKOVSKY, G
    SKINNER, DG
    [J]. JOURNAL OF UROLOGY, 1992, 147 (03) : 900 - 902
  • [2] [Anonymous], UROLOGIC PATHOLOGY
  • [3] Arterbery VE, 1997, SEMIN SURG ONCOL, V13, P461, DOI 10.1002/(SICI)1098-2388(199711/12)13:6<461::AID-SSU11>3.0.CO
  • [4] 2-W
  • [5] SHORT-TERM OUTCOMES AFTER CRYOSURGICAL ABLATION OF THE PROSTATE IN MEN WITH RECURRENT PROSTATE CARCINOMA FOLLOWING RADIATION-THERAPY
    BALES, GT
    WILLIAMS, MJ
    SINNER, M
    THISTED, RA
    CHODAK, GW
    [J]. UROLOGY, 1995, 46 (05) : 676 - 680
  • [6] Biochemical disease-free survival following I-125 prostate implantation
    Beyer, DC
    Priestley, JB
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03): : 559 - 563
  • [7] PROSTATE-SPECIFIC ANTIGEN BASED DISEASE-CONTROL FOLLOWING ULTRASOUND-GUIDED (125)IODINE IMPLANTATION FOR STAGE T1/T2 PROSTATIC-CARCINOMA
    BLASKO, JC
    WALLNER, K
    GRIMM, PD
    RAGDE, H
    [J]. JOURNAL OF UROLOGY, 1995, 154 (03) : 1096 - 1099
  • [8] Blasko John C., 1994, International Journal of Radiation Oncology Biology Physics, V30, P219, DOI 10.1016/0360-3016(94)90738-2
  • [9] Butler EB, 1997, SEMIN SURG ONCOL, V13, P406, DOI 10.1002/(SICI)1098-2388(199711/12)13:6<406::AID-SSU4>3.0.CO
  • [10] 2-E